ARCH Overage Fund
3
50M
3
3
- Areas of investment
Summary
Among the most popular portfolio startups of the fund, we may highlight Twist Bioscience, Homology Medicines, Quanterix. The fund has exact preference in some founders of portfolio startups. Among the most popular fund investment industries, there are Genetics, Analytics. Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund.
Speaking about the real fund results, this VC is 13 percentage points more often commits exit comparing to other organizations. The top amount of exits for fund were in 2018. The usual things for fund are deals in the range of 50 - 100 millions dollars. The fund is constantly included in less than 2 investment rounds annually. The important activity for fund was in 2016. Opposing the other organizations, this ARCH Overage Fund works on 71 percentage points more the average amount of lead investments.
The typical case for the fund is to invest in rounds with 7-8 participants. Despite the ARCH Overage Fund, startups are often financed by ARCH Venture Partners, Tao Venture Partners, Paladin Capital Group. The meaningful sponsors for the fund in investment in the same round are ARCH Venture Partners, Cormorant Asset Management, WuXi Healthcare Ventures. In the next rounds fund is usually obtained by Vivo Capital, Vida Ventures, Temasek Holdings.
Investments analytics
Analytics
- Total investments
- 3
- Lead investments
- 0
- Exits
- 3
- Investments by industry
- Biotechnology (3)
- Life Science (2)
- Health Care (2)
- Chemical (1)
- Pharmaceutical (1) Show 4 more
- Investments by region
-
- United States (3)
- Peak activity year
- 2016
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 9
- Group Appearance index
- 1.00
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
Company name | Deal date | Industry | Deal stage | Deal size | Location |
---|---|---|---|---|---|
Homology Medicines | 02 May 2016 | Biotechnology, Health Care, Genetics, Alternative Medicine | Early Stage Venture | 43M | United States, Massachusetts |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.